

# Voluntary exercise together with oral caffeine markedly stimulates UVB light-induced apoptosis and decreases tissue fat in SKH-1 mice

Yao-Ping Lu\*, Bonnie Nolan†, You-Rong Lou\*, Qing-Yun Peng\*, George C. Wagner<sup>†‡</sup>, and Allan H. Conney\*<sup>§</sup>

\*Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, †Department of Neuroscience, and ‡Department of Psychology, Rutgers, the State University of New Jersey, Piscataway, NJ 08854

Contributed by Allan H. Conney, June 21, 2007 (sent for review April 17, 2007)

Treatment of SKH-1 mice orally with caffeine (0.1 mg/ml in the drinking water), voluntary running wheel exercise, or a combination of caffeine and exercise for 2 weeks (*i*) decreased the weight of the parametrial fat pads by 35, 62, and 77%, respectively; (*ii*) decreased the thickness of the dermal fat layer by 38, 42, and 68%, respectively; (*iii*) stimulated the formation of UVB-induced apoptotic sunburn cells in the epidermis by 96, 120, and 376%, respectively; and (*iv*) stimulated the formation of UVB-induced caspase 3 (active form)-positive cells in the epidermis by 92, 120, and 389%, respectively (average of two experiments). Oral administration of caffeine (0.4 mg/ml in the drinking water) in combination with voluntary exercise was less effective than administration of the low dose of caffeine in combination with exercise in stimulating UVB-induced apoptosis. Although orally administered caffeine (0.1 mg/ml in the drinking water) or voluntary exercise for 2 weeks caused only a small nonsignificant stimulation of UVB-induced increase in the percentage of phospho-p53 (Ser-15)-positive cells in the epidermis (27 or 18%, respectively), the combination of the two treatments enhanced the UVB-induced increase in phospho-p53 (Ser-15)-positive cells by 99%. The plasma concentration of caffeine in mice ingesting caffeine (0.1–0.4 mg/ml drinking water) is similar to that in the plasma of most coffee drinkers (one to four cups per day). Our studies indicate a greater than additive stimulatory effect of combined voluntary exercise and oral administration of a low dose of caffeine on UVB-induced apoptosis.

methylxanthines | physical activity | programmed cell death | skin cancer | sunburn

In earlier studies we demonstrated that oral administration of caffeine or voluntary running wheel (RW) exercise decreased tissue fat (1–3), stimulated UVB light-induced apoptosis (3, 4), and inhibited UVB-induced carcinogenesis in SKH-1 mice (2, 5, 6). These treatments had no effect on body weight. It was of interest that the proapoptotic effects of these treatments were selective because they enhanced apoptosis in UVB-treated epidermis and in UVB-induced tumors, but the treatments had no effect on apoptosis in normal epidermis or in nontumor areas in tumor-bearing mice (1–5). The results of these studies suggest that the proapoptotic effects of caffeine administration and voluntary exercise are important for the inhibitory effects of these regimens on UVB-induced carcinogenesis.

In the present work, we determined the effects of a combination of voluntary RW exercise and oral administration of caffeine on UVB-induced apoptosis in SKH-1 mice. The results indicated a greater than additive stimulatory effect of voluntary RW exercise, when combined with a low dose of caffeine, on UVB-induced apoptosis.

## Results

**Effects of Voluntary RW Exercise and Oral Administration of Caffeine on Body Weight, Food Consumption, and Fluid Consumption in SKH-1 Mice.** Treatment of female SKH-1 mice with RW, caffeine (0.1 mg/ml in the drinking water), caffeine (0.4 mg/ml), RW + caffeine (0.1 mg/ml) or RW + caffeine (0.4 mg/ml) for 2 weeks

did not have a statistically significant effect on body weight or food consumption. In an earlier study, we found that voluntary RW exercise for several months increased both food consumption and fluid intake without having an effect on body weight (2).

In the present study, the average daily fluid consumption  $\pm$  SE by control mice or mice treated with RW, caffeine (0.1 mg/ml), caffeine (0.4 mg/ml), RW + caffeine (0.1 mg/ml), or RW + caffeine (0.4 mg/ml) for 2 weeks was  $7.97 \pm 0.22$  ml,  $9.66 \pm 0.14$  ml (21.3%  $\uparrow$ ;  $P = 0.006$ ),  $9.76 \pm 0.19$  ml (22.5%  $\uparrow$ ;  $P = 0.004$ ),  $8.53 \pm 0.42$  ml (7.0%  $\uparrow$ ;  $P > 0.1$ ),  $11.45 \pm 0.39$  ml (43.7%  $\uparrow$ ;  $P < 0.001$ ), or  $9.36 \pm 0.67$  ml (17.4%  $\uparrow$ ;  $P = 0.02$ ), respectively (results from two experiments). The daily dose of caffeine in mice treated with caffeine (0.1 mg/ml), caffeine (0.4 mg/ml), RW + caffeine (0.1 mg/ml), or RW + caffeine (0.4 mg/ml) was 38, 130, 43, or 144 mg/kg, respectively (average of two experiments). There was some variation in RW activity among different mice in the RW group, but the relatively small SE among different mice for tissue fat reduction in the RW group suggests relatively small interindividual differences in RW activity among the different mice.

Although it was difficult to determine the distance run by individual RW mice because there were five mice per cage and sometimes more than one mouse at a time was on the RW, we estimate that the RW mice ran  $\approx 2$  miles per day, and this distance was not significantly different from that run by the RW + caffeine (0.1 mg/ml) or from the RW + caffeine (0.4 mg/ml) group (average of two experiments).

**Effect of Voluntary RW Exercise in Combination with Oral Administration of Caffeine on Tissue Fat.** Treatment of SKH-1 mice with RW, caffeine (0.1 mg/ml), caffeine (0.4 mg/ml), RW + caffeine (0.1 mg/ml), or RW + caffeine (0.4 mg/ml) for 2 weeks decreased the weight of the parametrial fat pads by 62%, 35%, 58%, 77%, and 83%, respectively (average of two experiments), and the thickness of the dermal fat layer was decreased by 42%, 38%, 57%, 68%, and 77%, respectively (average of two experiments) (Fig. 1). The results indicate that oral administration of the low dose of caffeine together with RW has a greater effect on tissue fat than either treatment alone.

**Effect of Voluntary RW Exercise in Combination with Oral Administration of Caffeine on UVB-Induced Increase in Apoptosis.** A previous study on the time course for UVB-induced apoptosis indicated that peak effects occurred at 6–10 h after UVB, and caffeine admin-


Author contributions: Y.-P.L., G.C.W., and A.H.C. designed research; Y.-P.L., B.N., Y.-R.L., and Q.-Y.P. performed research; Y.-P.L., G.C.W., and A.H.C. analyzed data; and Y.-P.L. and A.H.C. wrote the paper.

The authors declare no conflict of interest.

Abbreviations: IGF-1, insulin-like growth factor 1; RW, running wheel.

<sup>§</sup>To whom correspondence should be addressed at: Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, 164 Frelinghuysen Road, Piscataway, NJ 08854-8020. E-mail: aconney@rci.rutgers.edu.

© 2007 by The National Academy of Sciences of the USA



**Fig. 1.** Effect of voluntary RW exercise, oral administration of caffeine, or a combination of exercise and caffeine on tissue fat. SKH-1 mice (10 per group) were treated with RW exercise, oral caffeine [0.1 or 0.4% in the drinking water (0.1 or 0.4 CF)], or a combination of RW and CF for 2 weeks. The weight of the parametrial fat pads and the thickness of the dermal fat layer were determined. Using Tukey's multiple comparison test for parametrial fat pad measurements, we found that the CF (0.1) + RW group was different from the CF (0.1) group in experiments 1 and 2. For the thickness of the dermal fat layer, the CF (0.1) + RW group was different from the CF (0.1) group in experiment 1 and from the RW group in experiments 1 and 2. When we combined data from experiments 1 and 2, the dermal fat thickness from animals treated with CF (0.1) + RW was significantly different from the dermal fat thickness in animals treated with CF (0.1) ( $P < 0.01$ ).

istration enhanced apoptosis at 6–10 h after UVB (4). Accordingly, we studied the effects of caffeine administration and RW for 2 weeks on UVB-induced apoptosis at 6 h after UVB.

Treatment of SKH-1 mice with RW, caffeine (0.1 mg/ml), caffeine (0.4 mg/ml), RW + caffeine (0.1 mg/ml), or RW + caffeine (0.4 mg/ml) for 2 weeks stimulated UVB-induced increases in apoptotic sunburn cells by 120%, 96%, 217%, 376%, and 258%, respectively, at 6 h after UVB (average of two experiments), and UVB-induced increases in caspase 3 (active form)-positive cells were enhanced by 120%, 92%, 207%, 389%, and 237%, respectively (average of two experiments) (Fig. 2). The results indicate that the low dose of caffeine in combination with RW had a greater than additive effect in enhancing UVB-induced apoptosis, whereas the high dose of caffeine in combination with RW was less effective than the low dose of caffeine in combination with RW.

#### Effect of Voluntary RW Exercise in Combination with Oral Administration of Caffeine on UVB-Induced Increase in Phospho-p53 (Ser-15).

Treatment of SKH-1 mice with RW, caffeine (0.1 mg/ml), caffeine (0.4 mg/ml), RW + caffeine (0.1 mg/ml), or RW + caffeine (0.4 mg/ml) stimulated UVB-induced increases in phospho-p53 (Ser-15) in the epidermis by 18%, 27%, 74%, 99% and 90%, respectively (average of two experiments) (Fig. 3). The results indicate that RW exercise or the low dose of caffeine had only a very small stimulatory effect on UVB-induced increase in phospho-p53 (Ser-15) (not statistically significant), but a combination of the two treatments stimulated the UVB-induced increase by 99%.

#### Relationship Between the Thickness of the Dermal Fat Layer and UVB-Induced Apoptosis.


In two separate experiments, we used the Pearson correlation coefficient for evaluating the relationship between the thickness of the dermal fat layer and UVB-induced increase in apoptosis in individual control mice and mice treated with RW, caffeine (0.1 mg/ml), caffeine (0.4 mg/ml), RW + caffeine (0.1 mg/ml), and RW + caffeine (0.4 mg/ml) (60 mice).

In experiment 1, we found a statistically significant inverse relationship between the dermal fat thickness in individual mice and UVB-induced increase in apoptotic sunburn cells ( $P < 0.0001$ ;  $r = -0.50$ ) and for fat thickness vs. caspase 3-positive cells ( $P = 0.002$ ;  $r = -0.39$ ). In experiment 2, there was also a significant relationship between dermal fat thickness in individual mice and UVB-induced increase in apoptotic sunburn cells ( $P = 0.003$ ;  $r = -0.37$ ) or UVB-induced increase in caspase 3-positive cells ( $P = 0.003$ ;  $r = -0.37$ ). Although there was a highly significant inverse relationship between the thickness of the dermal fat layer and UVB-induced apoptosis, the relatively low  $r$  value indicates that factors in addition to tissue fat may also play a role in modifying UVB-induced apoptosis.

#### Discussion

In earlier studies, we showed that voluntary RW exercise or oral administration of caffeine for 2 weeks stimulated UVB-induced apoptosis in SKH-1 mice (3, 4). In the present work, we demonstrated that combined exercise and oral administration of a low dose of caffeine (0.1 mg/ml in the drinking water) for 2 weeks resulted in a greater than additive increase in UVB-induced apoptosis compared with the effects of exercise or caffeine alone (Fig. 2). Although we cannot do a formal evaluation for synergistic effects because there was only one intensity of voluntary exercise, the results suggest that treatment of mice with a combination of RW exercise and an orally administered low dose of caffeine (0.1 mg/ml) may have had a synergistic stimulatory effect on UVB-induced apoptosis. It will be of interest to do additional studies with lower dose levels of caffeine in combination with exercise.

It is difficult to extrapolate the effect of caffeine in mice to that in humans based on dose because of differences in the rates of metabolism of caffeine in mice and humans. Mice metabolize caffeine with a half-life of  $\approx 45$  min (7, 8), whereas humans metabolize caffeine with a half-life of  $\approx 5$  h (9). Because of these



**Fig. 2.** Effect of voluntary RW exercise, oral administration of caffeine, or a combination of exercise and caffeine on UVB-induced apoptosis in the epidermis. SKH-1 mice (10 per group) were treated with RW exercise, oral caffeine [0.1 or 0.4% in the drinking water (0.1 or 0.4 CF)], or a combination of RW and CF for 2 weeks. Apoptotic sunburn cells and caspase 3 (active form)-positive cells in the epidermis were determined at 6 h after irradiation with UVB (30 mJ/cm<sup>2</sup>). Using Tukey's multiple comparison test for apoptotic sunburn cell measurements, we found that the CF (0.1) + RW group was different from the CF (0.1) group in experiments 1 and 2 and from the RW group in experiments 1 and 2. For the caspase 3 measurements, the CF (0.1) + RW group was different from the CF (0.1) group in experiments 1 and 2 and from the RW group in experiments 1 and 2.

considerations, it is better to compare the action of caffeine in animals and humans based on blood levels rather than on dose.

In an earlier study, we found that oral administration of caffeine (0.4 mg/ml in the drinking water) to SKH-1 mice resulted in an average caffeine plasma concentration of 16  $\mu$ M (10), which is equivalent to the plasma concentration of caffeine observed in people drinking three to five cups of coffee per day (11). In the present work, oral administration of caffeine (0.1 mg/ml) would be expected to have a plasma concentration similar to that observed in people drinking only one or two cups of coffee per day.

Previously, we showed that the stimulatory effect of caffeine administration on UVB-induced apoptosis was via a p53-dependent as well as a p53-independent pathway (4, 12). In additional studies, we showed that the stimulatory effect of voluntary exercise on UVB-induced apoptosis was predominantly via a p53-independent pathway (3). Although voluntary exercise or oral administration of a low dose of caffeine (0.1 mg/ml in the drinking water) had only a very small nonsignificant stimulatory effect on UVB-induced formation of phospho-p53 (Ser-15), a greater than additive effect was observed in exercising mice that were also treated with a low dose of caffeine (Fig. 3). The mechanism of the greater than additive effect of exercise and caffeine administration on UVB-induced apoptosis is not known.

In recent studies, we found that oral administration of caffeine inhibited the UVB-induced increase in epidermal phospho-Chk1

(Ser-345) and prematurely increased the level of epidermal cyclin B1 as well as the number of mitotic cells with cyclin B1.<sup>†</sup> The time course for these effects was similar to the time course for the effect of caffeine on UVB-induced apoptosis, suggesting that caffeine abrogated the G<sub>2</sub>/M checkpoint thereby causing lethal mitosis and apoptosis in UVB-treated animals.<sup>†</sup> In the present work, we found that voluntary exercise or oral administration of caffeine (0.1 mg/ml in the drinking water) also prematurely increased the level of cyclin B1 in the epidermis of UVB-treated mice, and a combination of RW exercise and caffeine administration had a greater effect for prematurely increasing the level of epidermal cyclin B1 than exercise or caffeine administration alone (Western blot study; data not shown). These results suggest that both caffeine administration and voluntary exercise may modulate the effect of UVB on the ATR/Chk1/cyclin B1 pathway and override the G<sub>2</sub>/M checkpoint to cause lethal mitosis and apoptosis. The results of our studies suggest that the greater than additive effects of voluntary exercise and administration of caffeine on UVB-induced apoptosis may result from an increased level of phospho-p53 (Ser-15) combined with a premature increase in cyclin B1 that results in mitotic catastrophe and apoptosis. Further mechanistic studies are needed.

<sup>†</sup>Lu, Y.-P., Lou, Y.-R., Peng, Q.-Y., Xie, J.-G., Nghiem, P., and Conney, A. H. (2007) *Proc. Am. Assoc. Cancer Res.* 48:821 (abstr.).



In summary, the results presented here suggest that oral administration of a low physiologically relevant dose of caffeine (0.1 mg/ml in the drinking water) together with voluntary exercise has a greater than additive stimulatory effect on UVB-induced apoptosis. These results suggest a need for further studies to determine the effects of combinations of voluntary exercise and orally administered low-dose levels of caffeine on UVB-induced carcinogenesis in animal models as well as studies to determine the effects of caffeine or caffeine-containing beverages in combination with exercise on the formation of sunlight-induced actinic keratoses and squamous cell carcinomas in humans.

## Materials and Methods

**Animals.** Female SKH-1 hairless mice (6–7 weeks old) were purchased from the Charles River Breeding Laboratories (Wilmington, MA), and the animals were kept in our animal facility for at least 1 week before use. Mice were housed in a temperature- and humidity-controlled room with free access to water and a Purina laboratory chow 5001 diet from the Ralston Purina Co. (St. Louis, MO), and they were kept on a 12-h light/12-h dark cycle.

**Exposure to UVB.** The UV lamps used (FS72T12-UVB-HO; National Biological Corp., Twinsburg, OH) emitted UVB (280–320 nm; 75–80% of total energy) and UVA (320–375 nm; 20–25% of total energy). The dose of UVB was quantified with a UVB Spectra 305 dosimeter (Daavlin Co., Byran, OH). The radiation was further calibrated with a model IL-1700 research radiometer/photometer (International Light, Inc., Newburyport, MA).

**Voluntary Exercise, Caffeine Administration, and the Preparation of Skin Sections.** For studies on the effect of voluntary RW exercise and caffeine administration on UVB-induced apoptosis in the epidermis of SKH-1 mice, female SKH-1 mice (7–8 weeks old, 10 mice per group) were placed in cages with a RW (13.75-cm diameter; 7 cm width) with free access to the wheel 24 h/day for 2 weeks (five mice per cage). Other mice with matched body weights and age were placed in cages without a RW and served as controls. The wheels were attached to a permanent magnetic switch that activated a digital counter to count wheel revolutions. Total wheel revolutions were recorded daily, with total distance run per day determined by multiplying the number of wheel rotations by the circumference of the wheel. A water bottle containing water or caffeine (0.1 or 0.4 mg/ml) was attached at the top of the cage unit. After 2 weeks of voluntary RW exercise with or without caffeine administration, the treated mice and their controls were irradiated once with 30 mJ/cm<sup>2</sup> of UVB and killed 6 h later. Our previous studies showed that 6–10 h after a single irradiation with UVB is the peak time for the formation of UVB-induced apoptotic sunburn cells (4, 64). The two parametrial fat pads were removed and weighed. The skin samples (≈2 cm long and 0.5 cm wide), were taken from the middle of the back, stapled flat to a plastic sheet and placed in 10% phosphate-buffered formalin at 4°C for 18–24 h. The skin samples were then dehydrated in ascending concentrations of ethanol (80%, 95%, and 100%), cleared in xylene, and embedded in Paraplast (Oxford Labware, St. Louis, MO). Four-micrometer serial sections of skin containing epidermis and

dermis were made, deparaffinized, rehydrated with water, and used for regular H&E or immunohistochemical staining. The thickness of the dermal fat layer was measured by using an ocular micrometer with an Olympus BHTU light microscope (Olympus America, Inc., Melville, NY) under ×100 magnification at 5–10 representative areas per slide and averaged (1). Apoptotic sunburn cells and caspase 3-positive cells labeling were determined as described previously (64).

**Measurement of Apoptotic Sunburn Cells.** Identification of apoptotic sunburn cells was based morphologically on cell shrinkage and nuclear condensation as we have done previously (64). Apoptotic sunburn cells were identified by their intensely eosinophilic cytoplasm and small, dense nuclei, which was observed in H&E-stained histological sections of the skin by using light microscopy. The percentage of apoptotic sunburn cells in the epidermis (basal plus suprabasal layers) was calculated from the number of these cells per 100 cells counted from the entire 20-mm length of epidermis for each skin section.

**Caspase 3 Immunostaining.** Affinity-purified polyclonal rabbit antibody that reacts with the mouse p20 subunit of caspase 3 but does not react with the precursor form was purchased from R&D Systems, Inc. (Minneapolis, MN). Skin sections used for the measurement of caspase 3 were stained by the horseradish peroxidase-conjugated avidin method as described previously (64). Endogenous peroxidase was blocked by incubating the tissue sections in 3% hydrogen peroxide in methanol for 30 min at room temperature. Sections were then treated with 0.01 M sodium citrate buffer (pH 6.0) in a microwave oven at high temperature for 10 min. The sections were incubated with a protein block (normal goat serum) for 10 min followed by avidin D for 15 min and biotin blocking solution for 15 min (avidin/biotin blocking kit from Vector Laboratories, Burlingame, CA) at room temperature. The sections were incubated with caspase 3 primary antibody (1:2,000 dilution) for 30 min at room temperature followed by incubation with a biotinylated anti-rabbit secondary antibody for 30 min and incubation with conjugated-avidin solution (ABC elite kit purchased from Vector Laboratories) for 30 min. Color development was achieved by incubation with 0.02% 3,3'-diaminobenzidine tetrahydrochloride containing 0.02% hydrogen peroxide for 10 min at room temperature. The slides were then counterstained with hematoxylin and dehydrated and coverslips were added for permanent mounting. A positive reaction was shown as a light brown to dark brown precipitate in the cytoplasm and/or perinuclei of the cells.

The percentage of caspase 3-positive cells in the epidermis was calculated from the number of stained caspase 3-positive cells per 100 epidermal cells counted from the entire 20-mm length of epidermis.

**Statistics.** The statistical evaluation of differences between different groups was done with Tukey's multiple comparison test (65).

We thank Drs. Weichung Joe Shih and Yong Lin for help with the statistical analysis of the data and Florence Florek for assistance in the preparation of the manuscript. This work was supported in part by National Institutes of Health Grant RO3 CA 121418 (to Y.-P.L.).

1. Lu Y-P, Lou Y-R, Lin Y, Shih WJ, Huang M-T, Yang CS, Conney AH (2001) *Cancer Res* 61:5002–5009.
2. Michna L, Wagner GC, Lou Y-R, Xie J-G, Peng Q-Y, Lin Y, Carlson K, Shih WJ, Conney AH, Lu Y-P (2006) *Carcinogenesis* 27:2108–2115.
3. Lu Y-P, Lou Y-R, Nolan B, Peng Q-Y, Xie J-G, Wagner GC, Conney AH (2006) *Proc Natl Acad Sci USA* 103:16301–16306.
4. Lu Y-P, Lou Y-R, Li X-H, Xie J-G, Brash D, Huang M-T, Conney AH (2000) *Cancer Res* 60:4785–4791.
5. Huang M-T, Xie J-G, Wang Z-Y, Ho C-T, Lou Y-R, Wang C-X, Hard GC, Conney AH (1997) *Cancer Res* 57:2623–2629.
6. Lou Y-R, Lu Y-P, Xie J-G, Huang M-T, Conney AH (1999) *Nutr Cancer* 33:146–153.
7. Nau H (1986) *Environ Health Perspect* 70:113–129.
8. Hartmann M, Czok G (1980) *Z Ernahrungswiss* 19:215–227.
9. Gilman AG, Goodman LS, Rall TW, Murad F, eds (1985) *Goodman and Gilman's: The Pharmacological Basis of Therapeutics* (Macmillan, New York) 7th Ed, p 1673.

10. Conney AH, Zhou S, Lee MJ, Xie J-G, Yang CS, Lou Y-R, Lu Y-P (2007) *Toxicol Appl Pharmacol*, in press.
11. de Leon J, Diaz FJ, Rogers T, Browne D, Dinsmore L, Ghosheh OH, Dwoskin LP, Crooks PA (2003) *Prog Neuropsychopharmacol Biol Psychiatry* 27:165–171.
12. Lu Y-P, Lou Y-R, Peng Q-Y, Xie J-G, Conney AH (2004) *Cancer Res* 64:5020–5027.
13. Potter JD (2006) *Epidemiology* 17:124–127.
14. Daniels J (2006) *Am J Nurs* 106:40–49.
15. Pischon T, Lahmann PH, Boeing H, Friedenreich C, Norat T, Tjønneland A, Halkjaer J, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, et al. (2006) *J Natl Cancer Inst* 98:920–931.
16. Frezza EE, Wachtel MS, Chiriva-Internati M (2006) *Gut* 55:285–291.
17. MacInnis RJ, English DR, Hopper JL, Gertig DM, Haydon AM, Giles GG (2006) *Int J Cancer* 118:1496–1500.
18. Moore LL, Bradlee ML, Singer MR, Splansky GL, Proctor MH, Ellison RC, Kregar BE (2004) *Int J Obesity-Related Metabol Disorders* 28:559–567.
19. Samanic C, Chow WH, Gridley G, Jarvholm B, Fraumeni JF, Jr (2006) *Cancer Causes Control* 17:901–909.
20. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) *N Engl J Med* 348:1625–1638.
21. Rapp K, Schroeder J, Klenk J, Stoehr S, Ulmer H, Concin H, Diem G, Oberaigner W, Weiland SK (2005) *Br J Cancer* 93:1062–1067.
22. Lorincz AM, Sukumar S (2006) *Endocrine-Related Cancer* 13:279–292.
23. Carmichael AR (2006) *Int J Obstet Gynaecol* 113:1160–1166.
24. Rodriguez C, Freedland SJ, Deka A, Jacobs EJ, McCullough ML, Patel AV, Thun MJ, Calle EE (2007) *Cancer Epidemiol Biomarkers Prev* 16:63–69.
25. Gong Z, Neuhauser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, Lippman SM, Platz EA, Pollak MN, Thompson IM, et al. (2006) *Cancer Epidemiol Biomarkers Prev* 15:1977–1983.
26. Samanic C, Gridley G, Chow WH, Lubin J, Hoover RN, Fraumeni JF, Jr (2004) *Cancer Causes Control* 15:35–43.
27. Gallus S, Naldi L, Martin L, Martinelli M, La Vecchia, C, Oncology Study Group of the Italian Group for Epidemiologic Research in D (2006) *Melanoma Res* 16:83–87.
28. Ji LL (2002) *Ann NY Acad Sci* 959:82–92.
29. Ahima RS, Flier JS (2000) *Trends Endocrinol Metabol* 11:327–332.
30. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW (1999) *Arterioscler Thromb Vasc Biol* 19:972–978.
31. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM (1995) *J Clin Invest* 95:2409–2415.
32. Mohamed-Ali V, Bulmer K, Clarke D, Goodrick S, Coppack SW, Pinkney JH (2000) *Int J Obes* 24:S154–S155.
33. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW (1997) *J Clin Endocrinol Metab* 82:4196–4200.
34. Coppack SW (2001) *Proc Nutr Soc* 60:349–356.
35. Hotamisligil GS, Shargill NS, Spiegelman BM (1993) *Science* 259:87–91.
36. Fried SK, Bunkin DA, Greenberg AS (1998) *J Clin Endocrinol Metab* 83:847–850.
37. Mohamed-Ali V, Goodrick S, Bulmer K, Holly JM, Yudkin JS, Coppack SW (1999) *Am J Physiol* 277:E971–E975.
38. Tsigos C, Kyrou I, Chala E, Tsapogas P, Stavridis JC, Raptis SA, Katsilambros N (1999) *Metabolism* 48:1332–1335.
39. Lyngso D, Simonsen L, Bulow J (2002) *J Physiol (London)* 543:373–378.
40. Petersen AM, Pedersen BK (2005) *J Appl Physiol* 98:1154–1162.
41. Petersen AMW, Pedersen BK (2006) *J Physiol Pharmacol* 57(Suppl 10):43–51.
42. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO (2002) *Nat Med* 8:75–79.
43. Ogunwobi OO, Beales IL (2007) *Int J Colorectal Dis* 22:401–409.
44. Russo VC, Metaxas S, Kobayashi K, Harris M, Werther GA (2004) *Endocrinology* 145:4103–4112.
45. Dieudonne MN, Bussi ere M, Dos Santos E, Leneuve MC, Giudicelli Y, Pecquery R (2006) *Biochem Biophys Res Commun* 345:271–279.
46. Barnard RJ, Ngo TH, Leung PS, Aronson WJ, Golding LA (2003) *Prostate* 56:201–206.
47. Ngo TH, Barnard RJ, Leung PS, Cohen P, Aronson WJ (2003) *Endocrinology* 144:2319–2324.
48. Shors AR, Solomon C, McTiernan A, White E (2001) *Cancer Causes Control* 12:599–606.
49. Chao A, Connell CJ, Jacobs EJ, McCullough ML, Patel AV, Calle EE, Cokkinides VE, Thun MJ (2004) *Cancer Epidemiol Biomarkers Prev* 13:2187–2195.
50. Martinez ME (2005) *Recent Results Cancer Res* 166:177–211.
51. Gammon MD, John EM, Britton JA (1998) *J Natl Cancer Inst* 90:100–117.
52. Verloop J, Rookus MA, van der Kooy K, van Leeuwen FE (2000) *J Natl Cancer Inst* 92:128–135.
53. Rockhill B, Willett WC, Hunter DJ, Manson JE, Hankinson SE, Colditz GA (1999) *Arch Intern Med* 159:2290–2296.
54. Patel AV, Rodriguez C, Jacobs EJ, Solomon L, Thun MJ, Calle EE (2005) *Cancer Epidemiol Biomarkers Prev* 14:275–279.
55. Giovannucci EL, Liu Y, Leitzmann MF, Stampfer MJ, Willett WC (2005) *Arch Intern Med* 165:1005–1010.
56. Nilsen TI, Romundstad PR, Vatten LJ (2006) *Int J Cancer* 119:2943–2947.
57. Barnard RJ (2004) *Evid Based Complement Altern Med* 1:233–239.
58. Jacobson BK, Bjelke E, Kv ale G, Heuch I (1986) *J Natl Cancer Inst* 76:823–831.
59. Kurozawa Y, Ogimoto I, Shibata A, Nose T, Yoshimura T, Suzuki H, Sakata R, Fujita Y, Ichikawa S, Iwai N, et al. (2005) *Br J Cancer* 93:607–610.
60. Gelatti U, Covolo L, Franceschini M, Pirali F, Tagger A, Ribero ML, Trevisi P, Martelli C, Nardi G, Donato F (2005) *J Hepatol* 42:528–534.
61. Nkondjock A, Ghadirian P, Kotsopoulos J, Lubinski J, Lynch H, Kim-Sing C, Horsman D, Rosen B, Isaacs C, Weber B, et al. (2006) *Int J Cancer* 118:103–107.
62. (2004) *Harv Womens Health Watch* 12:2–4.
63. Smith BD, Gupta U, Gupta BS, eds (2007) *Caffeine and Activation Theory: Effects on Health and Behavior* (CRC, Boca Raton).
64. Lu Y-P, Lou Y-R, Li X-H, Xie J-G, Lin Y, Weichung JS, Conney AH (2002) *Oncol Res* 13:61–70.
65. Hochberg Y, Tamhane AC (1987) *Multiple Comparison Procedures* (Wiley, New York).